The estimated Net Worth of Julian Baker Bros. Advisors... is at least $4 Milion dollars as of 7 October 2016. Julian Advisors owns over 3,250,000 units of Idera Pharmaceuticals stock worth over $4,003,013 and over the last 9 years Julian sold IDRA stock worth over $0.
Julian has made over 2 trades of the Idera Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Julian bought 3,250,000 units of IDRA stock worth $6,500,000 on 7 October 2016.
The largest trade Julian's ever made was buying 3,250,000 units of Idera Pharmaceuticals stock on 7 October 2016 worth over $6,500,000. On average, Julian trades about 722,222 units every 0 days since 2016. As of 7 October 2016 Julian still owns at least 9,309,333 units of Idera Pharmaceuticals stock.
You can see the complete history of Julian Advisors stock trades at the bottom of the page.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... oraz Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: